Equities researchers at Evercore ISI started coverage on shares of Gamida Cell (NASDAQ:GMDA) in a research report issued on Tuesday, The Fly reports. The brokerage set an “outperform” rating on the stock.
A number of other brokerages have also issued reports on GMDA. Zacks Investment Research raised Gamida Cell from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, May 15th. Needham & Company LLC decreased their price objective on Gamida Cell from $19.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 21st. Piper Sandler assumed coverage on Gamida Cell in a report on Monday, May 25th. They issued an “overweight” rating and a $13.00 price objective for the company. Oppenheimer increased their price objective on Gamida Cell from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Finally, HC Wainwright assumed coverage on Gamida Cell in a report on Monday, April 27th. They issued a “buy” rating and a $15.00 target price for the company. Nine research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $15.00.
Gamida Cell stock traded up $0.11 during midday trading on Tuesday, hitting $4.57. The stock had a trading volume of 114,644 shares, compared to its average volume of 187,463. The company has a current ratio of 4.15, a quick ratio of 4.15 and a debt-to-equity ratio of 0.19. The stock has a market cap of $109.73 million, a P/E ratio of -2.37 and a beta of 2.10. Gamida Cell has a 12 month low of $2.60 and a 12 month high of $7.70. The business has a fifty day moving average price of $5.17 and a 200 day moving average price of $4.45.
Gamida Cell (NASDAQ:GMDA) last posted its earnings results on Thursday, May 21st. The company reported ($0.31) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.12. On average, equities analysts anticipate that Gamida Cell will post -1.11 EPS for the current fiscal year.
An institutional investor recently bought a new position in Gamida Cell stock. UBS Group AG purchased a new stake in Gamida Cell Ltd (NASDAQ:GMDA) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,509 shares of the company’s stock, valued at approximately $28,000. Institutional investors own 21.76% of the company’s stock.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia.
Read More: Most Active Stocks
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.